Cabergoline
Back to searchMolecule Structure
Scientific Name
Cabergoline
Description of the Drug
Cabergoline is a dopamine receptor agonist used for the treatment of hyperprolactinemic conditions due to various causes.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00248
http://www.drugbank.ca/drugs/DB00248
Brand Name(s)
Cabaser, Cabergoline, Dostinex
Company Owner(s)
Apotex Corp, Ingenus Pharmaceuticals Llc, Ivax Pharmaceuticals Inc Sub Teva Pharmaceuticals Usa, Actavis Laboratories Fl Inc, Mylan Pharmaceuticals Inc, Strides Pharma Global Pte Ltd, Impax Laboratories Inc, Pfizer Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Dopamine D2 receptor | SINGLE PROTEIN | AGONIST | CHEMBL217 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL42292 | |
| PharmGKB | PA448708 | |
| Human Metabolome Database | HMDB0014393 | |
| DrugBank | DB00248 | |
| PubChem: Thomson Pharma | 14808642 | 14759961 |
| PubChem | 54746 | |
| LINCS | LSM-3939 | |
| Nikkaji | J134.029H | |
| BindingDB | 50426497 | |
| EPA CompTox Dashboard | DTXSID6022719 | |
| DrugCentral | 460 | |
| ChemicalBook | CB0282495 | |
| Guide to Pharmacology | 37 | |
| rxnorm | CABERGOLINE | |
| PubChem: Drugs of the Future | 12013713 | |
| KEGG Ligand | C08187 | |
| ChEBI | 3286 | |
| ZINC | ZINC000003800008 |
